Stock PCSA PROCESSA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Real-time Estimate Cboe BZX
Other stock markets
 13:20:28 2024-06-26 EDT 		5-day change 1st Jan Change
2.08 USD -0.24% Intraday chart for Processa Pharmaceuticals, Inc. +15.38% -68.62%
06-11 Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer CI
06-07 Top Premarket Decliners MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
AQ
Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer
CI
Top Premarket Decliners
MT
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
AQ
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
AQ
Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research
CI
Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.
CI
Certain Restricted Stock Units of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.
CI
Certain Options of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.
CI
Certain Common Stock of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.
CI
Top Premarket Decliners
MT
Top Midday Gainers
MT
HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target
MT
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
AQ
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial
CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
AQ
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
AQ
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PCSA Stock
  4. News Processa Pharmaceuticals, Inc.